Kaplan-Meier survival curves for the 21 patients with deletions that spanned the ABL/BCR fusion compared with all patients without deletions. (A) Overall survival, (B) survival censored at the time of switch to imatinib or allogeneic stem cell transplantation in the first chronic phase, (C) survival after allogeneic stem cell transplantation in the first chronic phase.